Barclays
EWTX icon

Barclays’s Edgewise Therapeutics EWTX Stock Holding History

Barclays’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.58M Sell
177,244
-195,494
-52% -$5.64M ﹤0.01% 1753
2025
Q4 		$9.25M Buy
372,738
+138,088
+59% +$2.77M ﹤0.01% 1734
2025
Q3 		$3.81M Sell
234,650
-46,600
-17% -$661K ﹤0.01% 2403
2025
Q2 		$3.69M Buy
281,250
+172,688
+159% +$2.49M ﹤0.01% 2361
2025
Q1 		$2.39M Sell
108,562
-25,095
-19% -$658K ﹤0.01% 2496
2024
Q4 		$3.57M Buy
133,657
+14,307
+12% +$456K ﹤0.01% 2448
2024
Q3 		$3.19M Buy
119,350
+88,826
+291% +$1.77M ﹤0.01% 2466
2024
Q2 		$550K Sell
30,524
-56,720
-65% -$989K ﹤0.01% 2984
2024
Q1 		$1.59M Sell
87,244
-691,672
-89% -$11M ﹤0.01% 2763
2023
Q4 		$8.52M Buy
778,916
+760,637
+4,161% +$5.34M ﹤0.01% 1634
2023
Q3 		$105K Buy
18,279
+1,003
+6% +$6.82K ﹤0.01% 3586
2023
Q2 		$134K Sell
17,276
-10,740
-38% -$90.6K ﹤0.01% 3436
2023
Q1 		$187K Buy
28,016
+9,783
+54% +$90.7K ﹤0.01% 3828
2022
Q4 		$163K Buy
18,233
+8,918
+96% +$83.6K ﹤0.01% 3961
2022
Q3 		$91K Sell
9,315
-209,993
-96% -$2.12M ﹤0.01% 3570
2022
Q2 		$1.75M Sell
219,308
-652
-0.3% -$4.93K ﹤0.01% 1952
2022
Q1 		$2.13M Buy
+219,960
New +$2.83M ﹤0.01% 1808

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Barclays's EWTX Position: Q1 2026 in Review

Barclays reduced its Edgewise Therapeutics (EWTX) stake by 52% in Q1 2026, selling an estimated $5.64M and leaving 177,244 shares worth $5.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1753.

Barclays first reported a position in EWTX in Q1 2022 and has held it in 17 quarters since. The position peaked at $9.25M in Q4 2025. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Barclays held 177,244 shares of Edgewise Therapeutics worth $5.58M as of Q1 2026.
  • Barclays sold 195,494 Edgewise Therapeutics shares in Q1 2026, an estimated $5.64M.
  • Edgewise Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1753 holding.
  • Barclays first reported a position in Edgewise Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Edgewise Therapeutics position peaked at $9.25M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.